Chad Hivnor, MD
Dermatology · San Antonio, TXNPI 1477544476
Payments from drug & device makers
Across 76 payments — averaging $127.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis, Inc$6K
- Lumenis BE Inc$1K
- AbbVie$838
- Johnson & Johnson$174
- Therakos LLC$127
- Sanofi$109
- plus $647 from 21 others
What the payments were for
- Speaking & faculty fees$6,46867%
- Food & beverage$3,21533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis, Inc | 1 | $6,468 |
| Lumenis BE Inc | 1 | $1,320 |
| AbbVie | 27 | $838 |
| Johnson & Johnson | 11 | $174 |
| Therakos LLC | 1 | $127 |
| Sanofi | 6 | $109 |
| Kyowa Kirin, Inc. | 1 | $101 |
| Amgen | 3 | $84 |
| Sun Pharmaceutical Industries Inc. | 3 | $78 |
| Mayne Pharma Commercial LLC | 2 | $39 |
| LEO Pharma Inc. | 2 | $35 |
| Galderma Laboratories, L.p. | 2 | $32 |
| Lilly USA, LLC | 2 | $27 |
| Revance Therapeutics, Inc. | 1 | $27 |
| Krystal Biotech Inc | 1 | $27 |
| UCB, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Cipher Pharmaceuticals US LLC | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Biofrontera Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $13 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $13 |
| Sientra, Inc. | 1 | $13 |
| Mylan Pharmaceuticals Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,682 in reported general payments places this provider in the 65th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 11 | $93,641 |
| Dupixent PenDupilumab | 14 | $51,826 |
| Doxycycline Hyclate | 53 | $2,430 |
| Clobetasol Propionate | 24 | $939 |
| Fluorouracil | 13 | $761 |
| Triamcinolone Acetonide | 44 | $448 |
| Ketoconazole | 31 | $342 |
| ValacyclovirValacyclovir Hcl | 22 | $248 |
| Clindamycin Phosphate | 12 | $188 |
| Doxycycline Monohydrate | 11 | $157 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Antonio
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
- Emily BeckerSan Antonio$2.4M
- William CragunSan Antonio$2.3M
- Steven DavisSan Antonio$1.8M
- Lindsey FinkleaSan Antonio$1.2M
- Stephen MillerSan Antonio$389K
- Vivian BucaySan Antonio$241K
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.